Aleafia Health - CEO, Tricia Symmes
CEO, Tricia Symmes
Source: Canadian Business
  • Aleafia Health (AH) has closed a private placement for gross proceeds of approximately $5.6 million
  • The company issued 68,151,515 units at a price of $0.0825 per unit
  • Net proceeds will be used to fund working capital and capital expenditures
  • Aleafia Health is a federally licensed Canadian cannabis company offering cannabis health and wellness services and products
  • Aleafia Health Inc. (AH) opened trading at C$0.07 per share

Aleafia Health (AH) has closed its previously announced private placement for gross proceeds of approximately $5.6 million.

The company issued 68,151,515 units at a price of $0.0825 per unit. Each unit consists of one common share  and one-half of one common share purchase warrant. Each warrant may be exercised into one common share at a price of $0.1025 until June 24, 2026.

The warrants are subject to an acceleration clause.

Net proceeds will be used to fund working capital and capital expenditures.

“The closing of the private placement is a significant milestone for Aleafia, providing funding to support our growth plans, and satisfying a main condition for the amendment of the company’s convertible debentures,” said Aleafia Health CEO Tricia Symmes.

Aleafia Health is a federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada. The company owns and operates a virtual network of medical cannabis clinics staffed by physicians and nurse practitioners.

Aleafia Health owns three licensed cannabis production facilities and operates a strategically located distribution centre in the province of Ontario, including the first large-scale, legal outdoor cultivation facility in Canadian history.

Aleafia Health Inc. (AH) opened trading at C$0.07 per share.

More From The Market Online

Tilray Brands launches health-conscious cannabis drinks

Tilray Brands (TSX:TLRY) showcases two new cannabis-infused beverages from XMG to court more health-conscious consumers.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

What is behind the latest cannabis stock jump?

In a groundbreaking move, the U.S. federal administration is set to reclassify cannabis as a lower-risk substance.
Negotiating in a meeting room

Hempalta acquires controlling interest in Hemp Carbon Standard

Hempalta (TSXV:HEMP) completes its acquisition of controlling interest in Hemp Carbon Standard equalling 50.1 per cent of shares.